Transurethral Prostatectomy with CC/MCC DRG Reimbursement

DRG 713 includes inpatient transurethral prostatectomy cases with a Major Complication or Comorbidity, covering higher-acuity surgical admissions for obstructive prostatic disease. This Diagnosis-Related Group matters for inpatient reimbursement because the presence of a Major Complication or Complication or Comorbidity increases Resource Intensity and leads to higher Medicare payment under inpatient prospective payment policies.

DRG 713 Overview

DRG 713 covers inpatient admissions for transurethral prostatectomy procedures performed for benign prostatic hyperplasia or other obstructive prostatic conditions when a Major Complication or Comorbidity is present. This Diagnosis-Related Group groups cases with higher resource use due to complicating diagnoses or perioperative issues that increase length of stay, intensity of care, and cost. It is important for Centers for Medicare & Medicaid Services payment because hospitals receive higher reimbursement under Medicare inpatient payment rules for cases assigned to this Diagnosis-Related Group compared with similar procedures without complications. Accurate documentation and coding of the surgical procedure and any Major Complication or Complication or Comorbidity affect assignment to this Diagnosis-Related Group and thus impact Medicare inpatient reimbursement.

Perioperative risk-reduction and complication-prevention trials: randomized or prospective cohort studies that test protocols (e.g., optimized perioperative fluid management, antibiotic prophylaxis strategies, or bleeding-control measures) to reduce immediate complications like hemorrhage, urinary retention, infection, or cardiovascular events in patients undergoing transurethral prostatectomy with significant comorbidity. These studies focus on older men with benign prostatic hyperplasia or obstructive urinary symptoms who also carry CC/MCC-level comorbidities (cardiovascular disease, anticoagulant use, chronic kidney disease), assessing short-term morbidity, length of stay, and readmission rates. Results directly inform perioperative care pathways and risk stratification used by clinicians and payers to reduce costly complications and inpatient resource utilization.
Comparative effectiveness trials of surgical approaches and technologies: head-to-head studies comparing different transurethral techniques, energy sources, or adjunctive intraoperative devices (including resection versus enucleation approaches or different hemostatic methods) in patients with large prostates or those at higher risk for intraoperative bleeding. These trials enroll inpatient populations requiring TURP-level intervention with CC/MCC to evaluate outcomes such as operative time, transfusion need, catheter duration, functional urinary outcomes, and complication profiles. Findings help hospitals and payers decide which technologies or surgical pathways yield the best value for complex patients who drive higher DRG costs.
Post-discharge recovery, quality-of-life, and resource-utilization studies: observational cohorts or pragmatic trials that follow patients from discharge to 30–90 days to measure functional recovery, urinary symptom trajectories, rehospitalizations, outpatient visits, and cost outcomes, often stratified by baseline comorbidity burden. These studies examine which discharge planning, home care, or outpatient follow-up strategies reduce readmissions and improve patient-reported outcomes in the older, comorbid population typical of DRG 713. Evidence from this research supports care-management programs and payer policies aimed at lowering post-acute utilization and improving long-term value for high-risk inpatient surgical populations.

Perioperative risk-reduction and complication-prevention trials: randomized or prospective cohort studies that test protocols (e.g., optimized perioperative fluid management, antibiotic prophylaxis strategies, or bleeding-control measures) to reduce immediate complications like hemorrhage, urinary retention, infection, or cardiovascular events in patients undergoing transurethral prostatectomy with significant comorbidity. These studies focus on older men with benign prostatic hyperplasia or obstructive urinary symptoms who also carry CC/MCC-level comorbidities (cardiovascular disease, anticoagulant use, chronic kidney disease), assessing short-term morbidity, length of stay, and readmission rates. Results directly inform perioperative care pathways and risk stratification used by clinicians and payers to reduce costly complications and inpatient resource utilization.
Comparative effectiveness trials of surgical approaches and technologies: head-to-head studies comparing different transurethral techniques, energy sources, or adjunctive intraoperative devices (including resection versus enucleation approaches or different hemostatic methods) in patients with large prostates or those at higher risk for intraoperative bleeding. These trials enroll inpatient populations requiring TURP-level intervention with CC/MCC to evaluate outcomes such as operative time, transfusion need, catheter duration, functional urinary outcomes, and complication profiles. Findings help hospitals and payers decide which technologies or surgical pathways yield the best value for complex patients who drive higher DRG costs.
Post-discharge recovery, quality-of-life, and resource-utilization studies: observational cohorts or pragmatic trials that follow patients from discharge to 30–90 days to measure functional recovery, urinary symptom trajectories, rehospitalizations, outpatient visits, and cost outcomes, often stratified by baseline comorbidity burden. These studies examine which discharge planning, home care, or outpatient follow-up strategies reduce readmissions and improve patient-reported outcomes in the older, comorbid population typical of DRG 713. Evidence from this research supports care-management programs and payer policies aimed at lowering post-acute utilization and improving long-term value for high-risk inpatient surgical populations.

OpenPayer

Summary & Overview

Transurethral Prostatectomy with CC/MCC: Inpatient Reimbursement Overview

DRG 713 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes